Will you recommend abemaciclib in combination with standard adjuvant endocrine therapy in patients with high risk hormone receptor positive, HER2- early breast cancer?

With the recent announcement that the phase 3 MonarchE trial met its primary endpoint.

Answer from: Medical Oncologist at Community Practice

While it is exciting to hear that abemaciclib offered an improvement in outcome when added to hormone therapy compared to hormone therapy alone in MONARCH-E, I would caution practicing by press release. The data have not been publicly reported yet. Perhaps there is a subgroup who are deriving the gr...

Comments

Medical Oncologist at University of Utah Huntsman Cancer Institute
I agree with the caution to avoid "practicing by p...

Answer from: Medical Oncologist at Community Practice

Exciting data, but I will wait to see the fine print if you will, as the PALLAS study was negative and we are still awaiting the NATALEE study results as well. Choosing the right patients for this approach will be key.

Answer from: Medical Oncologist at Academic Institution

I agree. We have a "journal club" style meeting planned where we will carefully look at what is available for MONARCH-E, PALLAS and NATALEE to compare inclusion criteria and available results. This will help us develop our plans for future patient selection... That said, I have started to mention t...

Please select the option that best describes you:

Will you recommend abemaciclib in combination with standard adjuvant endocrine therapy in patients with high risk hormone receptor positive, HER2- early breast cancer?

Related Questions